ClinicalTrials.gg
TerminatedNCT05117242Updated Sep 21, 2026

Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer

A Phase 2 interventional study of Acasunlimab and Pembrolizumab in Non Small Cell Lung Cancer Metastatic, sponsored by Genmab. Terminated at 40 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by Genmab · Phase 2, Interventional, and Treatment

Why this study was terminated
Genmab has decided to discontinue further clinical development of acasunlimab following strategic portfolio prioritization. The decision was not related to safety concerns.

From the registry’s dates

  • Primary completion was Dec 2024, 1 year 11 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Nov 2025.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
125
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Carcinoma, Non-Small-Cell Lung by Genmab — 2 open to participants now, 3 under way, none of them phase 3. Carcinoma, Non-Small-Cell Lung · Genmab.

Enrollment
5th of 10
125 · median 87
Started
2021
the only one that year
Phase 2
4 of 11
1 open now
Registered
8th of 11
by date

Among the 11 studies in Carcinoma, Non-Small-Cell Lung by Genmab, this one is the 5th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2021, is one of 4 in phase 2, and was the 8th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

2 of the 11 studies in Carcinoma, Non-Small-Cell Lung by Genmab are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Carcinoma, Non-Small-Cell Lung by Genmab, or all of them as a file.
02

Study summary

The goal of this clinical trial is to compare the safety and efficacy (how well the drug works) of acasunlimab (also known as GEN1046) when it is used alone (monotherapy) versus when it is combined with a cancer drug (pembrolizumab) for participants with relapsed/refractory (disease has returned after treatment or did not respond to treatment) non-small cell lung cancer (NSCLC; the most common type of lung cancer).

This trial has 2 parts. The purpose of the first part is to find out if the combination of acasunlimab and pembrolizumab is safe and to find out the best doses to use. The purpose of the second part is to give acasunlimab and pembrolizumab to more participants to evaluate efficacy. In the second part of the trial, participants will be randomized to participate in 1 of the 3 arms of the trial. Randomized means that the participant will be randomly assigned to a treatment arm based on chance; no one chooses their treatment arm.

Participants will receive either acasunlimab alone (100 followed by 500 mg into the vein) or acasunlimab with pembrolizumab (200 or 400 mg into the vein) once every 3 or 6 weeks, depending on which arm the participant is randomized into. All participants will receive active drug; no one will receive placebo.

Trial details include:

  • The average trial duration for an individual participant will be about 10 months.
  • The average treatment duration for an individual participant will be about 6 months.
  • The visit frequency will be weekly at first and lessening over time until visits are only once every 3 weeks.
03

Conditions studied

  • Non Small Cell Lung Cancer Metastatic

Keywords

  • DuoBody®
  • Bispecific antibody
  • PD-L1
  • 4-1BB
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Have signed an form (ICF)
  • Be at least 18 years of age.
  • Have or cytologically confirmed diagnosis of stage 4 NSCLC with at least 1 containing an /PD-L1 mAb for disease
  • Have a tumor PD-L1 expression result available prior to first treatment demonstrating PD-L1 expression in ≥1% of tumor cells as assessed by a central or local laboratory during screening.
  • Have per v1.1.
  • Have (ECOG) performance status (PS) ≤1.
  • Have of at least 3 months.
  • Have adequate organ and bone marrow function as defined in the protocol.

Key Exclusion Criteria:

  • Documentation of known EGFR, KRAS, RET, ROS1, BRAF mutations, NTRK gene infusions, RET arrangement, ALK gene rearrangements, high-level MET amplification, or METex 14 skipping. Note: Subjects harboring such mutations, gene rearrangements or amplifications may be enrolled in the trial, if subjects have received prior approved targeted therapy for such mutations, the subject may still be eligible for this trial.
  • Treatment with an anti-cancer agent within 28 days prior to acasunlimab administration.
  • Any agent (including investigational vaccines).
  • Radiotherapy within 14 days prior to first dose of acasunlimab. Note: palliative radiotherapy will be allowed for local pain control under certain conditions.
  • Chronic systemic doses, ie, prednisone >10 mg daily or a cumulative dose >150 mg prednisone within 14 days before the first acasunlimab administration.
  • Subject has severe (≥Grade 3) to pembrolizumab and/or any of its .
  • Subject has to the use of pembrolizumab per local prescribing information.
  • Subject has a history of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis (interstitial lung disease).
  • Ongoing or active infection requiring intravenous treatment with anti-infective therapy or any ongoing systemic inflammatory condition requiring further diagnostic work-up or management during screening.
  • Symptomatic congestive heart failure (grade III or IV as classified by the ), unstable angina pectoris, or cardiac arrhythmia.
  • Uncontrolled hypertension defined as systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg, despite optimal medical management.
  • Ongoing or recent (within 6 months) evidence of significant disease that required treatment with systemic immunosuppressive treatments, which may suggest risk for irAEs.
  • Subject has a known history of any of the following:

    1. Grade 3 or higher irAEs that led to treatment discontinuation of a prior immunotherapy treatment.
    2. Myositis, Guillain-Barré syndrome, or myasthenia gravis of any grade.
    3. Liver disease (eg, alcoholic hepatitis or non-alcoholic steatohepatitis, drug-related or autoimmune hepatitis, or evidence of hepatic cirrhosis).
    4. Organ allograft (except for corneal transplant) or or allogeneic bone marrow transplant, or stem cell rescue within 3 months prior to the first dose of acasunlimab.
    5. Grade 3 or higher allergic reactions to monoclonal antibody therapy as well as known or suspected allergy or intolerance to any agent given in the course of this trial.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
125 participants (actual)

Study arms

  • Experimental
    Arm A

    Treatment with acasunlimab once every 21 days for the first 2 cycles and then every 42 days in subsequent cycles

    Biological: Acasunlimab

  • Experimental
    Arm B

    Treatment with acasunlimab + pembrolizumab once every 21 days

    Biological: Acasunlimab · Biological: Pembrolizumab

  • Experimental
    Arm C

    Treatment with acasunlimab + pembrolizumab once every 42 days

    Biological: Acasunlimab · Biological: Pembrolizumab

Interventions

  • BiologicalAcasunlimab

    Acasunlimab will be administered intravenously (IV)

    Also known as: GEN1046, DuoBody®-PD-L1×4-1BB

  • BiologicalPembrolizumab

    Pembrolizumab will be administered IV

    Also known as: KEYTRUDA®

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR)

    ORR will be measured as the proportion of subjects with a confirmed response of complete response (CR) or partial response (PR) as per RECIST v1.1

    Time frame: From first treatment to approximately 27 weeks after last subject's first dose

Secondary outcomes

  1. Duration of response (DOR)

    DOR will be measured as the time from initial onset of CR or PR to first radiographic progression as per RECIST v. 1.1 or death from any cause, whichever occurs first.

    Time frame: From onset date of response until disease progression/death/lost to follow-up/start of new anticancer therapy or withdrawal of consent, whichever occurs first (an expected average of 6 months)

  2. Time to response (TTR)

    TTR will be measured as the time from first treatment to onset of initial response (CR or PR) as per RECIST v.1.1

    Time frame: From first treatment to date of onset of initial response (CR or PR) as per RECIST v.1.1 (an expected average of 6 months)

  3. Progression-free survival (PFS)

    PFS will be measured from date of first treatment until date of radiographic progression as per RECIST v.1.1 or until death from any cause, whichever occurs first

    Time frame: From first treatment to first documented progression or death due to any cause (an expected average of 6 months)

  4. Overall survival (OS)

    Defined as time to death from of any cause

    Time frame: From first treatment to date of death (assessed up to 3 years after the last participant's first dose in the trial)

  5. Incidence and severity of adverse events (AEs) and laboratory abnormalities

    Incidence of treatment-emergent AEs as assessed by CTCAE v5.0. Laboratory parameters graded by CTCAE v5.0

    Time frame: Throughout the trial until end of safety follow-up period (60 days or 90 days after last dose)

07

Study locations

40 sites
  • St. Joseph Heritage Healthcare
    Santa Rosa, California 95403, United States
  • Florida Cancer Specialists - FCS South
    Fort Myers, Florida 33901, United States
  • Florida Cancer Center
    St. Petersburg, Florida 33705, United States
  • Henry Ford Cancer Institute
    Detroit, Michigan 48202, United States
  • Cancer & Hematology Centers of Western Michigan CHCWM P.C.
    Grand Rapids, Michigan 49503, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Institut Bergonie
    Bordeaux, France
  • Hopital Morvan CHU de Brest
    Brest, France
  • Hopital Charles Nicolle Chu Rouen
    Rouen, France
  • Hopital dInstruction Des Armees Begin
    Saint-Mandé, France
  • Institut de Cancerologie Strasbourg Europe (ICANS)
    Strasbourg, France
  • Hôpital Foch
    Suresnes, France
  • Gustave Roussy
    Villejuif, France
  • Med.Hochschule Hannover Klinik für Pneumologie
    Hanover, Germany
  • Universitatsklinik Giessen und Marburg Standort Giessen
    Hessen, Germany
  • LKI Lungenfachklinik Immenhausen
    Immenhausen, Germany
  • Department of Internal Medicine II
    Regensburg, Germany
  • Azienda Ospedaliera Universitaria Policlinico G Rodolico San Marco
    Catania, Italy
  • IRCCS Istituto Europeo di Oncologia
    Milan, Italy
  • UOC Oncoematologia AOU L.Vanvitelli
    Naples, Italy
  • La Maddalena SPA
    Palermo, Italy
  • IFO Regina Elena
    Roma, Italy
  • Netherlands Cancer Institute
    Amsterdam, Netherlands
  • VU University Medical Center
    Amsterdam, Netherlands
  • Leids Universitair Medisch Centrum
    Leiden, Netherlands
  • Erasmus MC
    Rotterdam, Netherlands
  • Samodzielny Publiczny Zespol Gruzlicy i Chorob Pluc
    Olsztyn, Poland
  • Maria Sklodowska-Curie National Research Institute of Oncology
    Warsaw, Poland
  • Centro Clinico Champalimaud
    Lisbon, Portugal
  • Centro Hospitalar Universitário do Porto - Hospital de Santo Antonio
    Porto, Portugal
  • Hospital Universitari Vall dHebron
    Barcelona, Spain
  • Clinica Universidad de Navarra CUN
    Madrid, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, Spain
  • Hospital Universitario Fundacion Jimenez Diaz
    Madrid, Spain
  • MD Anderson Cancer Center
    Madrid, Spain
  • Hospital Universitario Virgen de la Victoria
    Málaga, Spain
  • Clinica Universidad de Navarra
    Pamplona, Spain
  • Fundacion Instituto Valenciano de Oncologia
    Valencia, Spain
  • Cheltenham General Hospital
    Cheltenham, United Kingdom
  • The Christie Hospital
    Manchester, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2021 to primary completion in Dec 2024, 37 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2021
First posted
Nov 11, 2021
StartActual
Oct 27, 2021
Primary completionActual
Dec 2, 2024
CompletionActual
Aug 31, 2026
Results delay requested
Nov 3, 2025
Last update
Sep 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05117242
Lead sponsor
Genmab
Responsible party
Sponsor
First posted
Nov 11, 2021
Start date
Oct 27, 2021
Primary completion
Dec 2, 2024
Completion
Aug 31, 2026
Last update
Sep 21, 2026

Study contacts

Study Official
study director · Genmab

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acasunlimab

Start the discussion